@cosair
Judging by what Starpharma just paid recently in December 2017 - the FDA submission will cost somewhere in the vicinity of $3-$5m (although the FDA refunded that to SPL almost immediately) it would still need to be paid upfront; and while a far cry from $35m I guess there are other expenses associated with GVHD that will come to light soon enough

.....
On another note - I agree with you
@antibody regarding the accumulation that is going on (and as mentioned earlier today in one of my posts) .... people forget that Teva dumping of shares was huge ... it allowed many shorts to cover without having to buy back on market .... literally millions of shares were absorbed (or soaked up as our illustrious leader would say ...hehe)
...... huge volumes of shares again last week and yet again this week being mopped up around the $1.80 mark ... almost 20m shares this week already between ASX and ChiX ... tells me instos want in .... obviously not that fussed about the $75m credit facility or its terms ????
..... regardless of what the naysayers are sprouting - it isn't mum and dad investors buying tens of millions of shares at around $1.80 each in the last couple of weeks - just sayin' ! 